angiotensin II antagonist

angiotensin II antagonist

One of a range of drugs that act directly on angiotensin at its receptor sites so as to block its action. These drugs include CANDESARTAN, IRBESARTAN, LOSARTAN, VALSARTAN, telmisartan (Micardis), Olmesartan (Olmetec) and eprosartan (Teveten).
References in periodicals archive ?
Racine-Poon, An Interaction Study with Cimetidine and the New Angiotensin II Antagonist Valsartan, Eur.
Antihypertensive medicines dispensed for free during SNP were: (i) beta-blocking agents: atenolol 25 mg and propranolol hydrochloride 40 mg; (ii) diuretics: hydrochlorothiazide 25 mg; and (iii) agents acting on the renin-angiotensin system inhibitors (Class C09 on European Pharmaceutical Marketing Research Association (EphMRA) Anatomical Classification) including (a) the angiotensin-converting-enzyme (ACE) inhibitors captopril 25 mg and enalapril maleate 10 mg; and (b) the angiotensin II antagonist or angiotensin receptor blocker (ARB) losartan potassium 50 mg (10).
The Heart Failure Endpoint Evaluation of Angiotensin II Antagonist Losartan (HEAAL) trial enrolled patients with symptomatic, New York Heart Association class II-IV heart failure who had a left ventricular ejection fraction of 40% or less.
Findings from the Irbesartan Diabetic Nephropathy Trial (IDNT) and the Reduction of Endpoints in NIDDM with Angiotensin II Antagonist Losartan (RENAAL) indicate that ARBs are more effective than other agents in slowing the progression of kidney disease in patients with macroalbuminuria due to type 2 diabetes.
COZAAR is the world's most widely prescribed medication in the angiotensin II antagonist class and it continues its strong growth, as physicians increasingly recognize the excellent tolerability and efficacy of these two products.
POPULATION STUDIED The Reduction of Endpoints in Non-insulin--dependent diabetes with the Angiotensin II Antagonist Losartan (RENAAL) study included 1513 people with type 2 diabetes and nephropathy, ranging in age from 31 to 70 years.
The supporting data come from several clinical trials, including the Reduction of Endpoints in NID-DM with the Angiotensin II Antagonist Losartan (RENAAL) study, as well as the Irbesartan Diabetic Nephropathy Trial (IDNT).
The supporting data come from several clinical trials, including the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study, as well as the Irbesartan Diabetic Nephropa thy Trial (IDNT).

Full browser ?